Immune system and malignant disease
Adjuvant treatment of operable node-positive and
operable node-negative breast cancer (in combination
with doxorubicin and cyclophosphamide) | Initial
chemotherapy of locally advanced or metastatic breast
cancer (with doxorubicin) | Locally advanced or
metastatic breast cancer where cytotoxic chemotherapy
with an anthracycline or an alkylating drug has failed
(monotherapy) | Locally advanced or metastatic breast
cancer where cytotoxic chemotherapy with an
anthracycline has failed (with capecitabine) | Initial
chemotherapy of metastatic breast cancer which
overexpresses human epidermal growth factor-2 (with
trastuzumab) | Locally advanced or metastatic non-small
cell lung cancer where previous chemotherapy has failed
| Initial chemotherapy of unresectable, locally advanced
or metastatic non-small cell lung cancer (with cisplatin) |
Hormone-resistant metastatic prostate cancer (in
combination with prednisone or prednisolone) | Initial
treatment of metastatic gastric adenocarcinoma,
including adenocarcinoma of the gastro-oesophageal
junction (with cisplatin and fluorouracil) | Induction
treatment of locally advanced squamous cell carcinoma
of the head and neck (with cisplatin and fluorouracil)
▶BY INTRAVENOUS INFUSION
▶Adult: (consult product literature or local protocols)
PDF page 997
NICE decisions
Immune system and malignant disease
▶Docetaxel for the treatment of hormone-refractory metastatic
prostate cancer (June 2006) NICE TA101
Docetaxel is an option for hormone-refractory metastatic
prostate cancer only if their Karnofsky score is at least 60%
[Karnofsky score is a measure of the ability to perform
ordinary tasks].
www.nice.org.uk/guidance/ta101
▶Pertuzumab with trastuzumab and docetaxel for treating
HER2-positive breast cancer (March 2018) NICE TA509
Pertuzumab, in combination with trastuzumab and
docetaxel, is recommended, within its marketing
authorisation, for treating HER2-positive metastatic or
locally recurrent unresectable breast cancer, in adults who
have not had previous anti-HER2 therapy or chemotherapy
for their metastatic disease, only if the manufacturer
provides pertuzumab within the agreed commercial access
arrangement.
www.nice.org.uk/guidance/ta509
Scottish Medicines Consortium (SMC) decisions
SMC No. 369/07
The Scottish Medicines Consortium has advised (May 2007)
that docetaxel (Taxotere ®) in combination with cisplatin
and fluorouracil is accepted for restricted use within NHS
Scotland for the induction treatment of patients with
unresectable locally advanced squamous cell carcinoma of
the head and neck.
SMC No. 481/08
The Scottish Medicines Consortium has advised (July
2008) that docetaxel (Taxotere ®) in combination with
cisplatin and fluorouracil is accepted for restricted use
within NHS Scotland for the induction treatment of
patients with resectable locally advanced squamous cell
carcinoma of the head and neck.
PDF page 998
